Company

Technology powers us. Drug development defines us.

Novorex is a drug development company integrating AI, FBDD, and biophysical validation to identify real binders and advance high-unmet-need CNS and inflammation pipelines.

01 / Company Overview

Seamless Drug Discovery for Real Binders

Novorex bridges theoretical prediction and real-world validation. The company combines Fragment-Based Drug Discovery, AI & in silico platforms, recombinant protein production, and biophysical assays to identify small molecules that truly bind to target proteins.

01 / 05

Core Position

Prediction & Validation connected as one company capability

Novorex is positioned around rational drug discovery for undruggable targets, unmet medical needs, First-in-Class and Best-in-Class small molecules. Its core message is not simply AI, but verified Real Binder discovery.

2020Established

26Employees

3 LabsPangyo / Central / Jeongeup

Real BinderPrediction + Validation

Integrated Capability

FBDDFragment-Based Drug Discovery for efficient hit discovery and fragment growth/linking.

AI & In silico PlatformDeepDesigner, NovoPicker, and NovoLibrary support generation, selection, and target-specific library strategy.

Biophysical ValidationSPR, NMR, X-ray and related assays confirm direct molecular-level binding.

Target EngagementExperimental evidence to reduce risk and support future licensing discussions.